Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

499
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
499
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
RNA Stability01:53

RNA Stability

31.6K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
31.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenic cell death as interplay between physical anticancer modalities and immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Gentle and efficient engineering of primary human NK cells by photoporation with polydopamine nanosensitizers.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Drying behaviour and visualization of surfactants after co-spray drying of surfactant-stabilized aqueous suspensions.

International journal of pharmaceutics·2023
Same author

Wire-bow in situ measurements for powerful control of wire-wear during diamond-wire crystalline silicon sawing.

The Review of scientific instruments·2022
Same author

Comparison of magnetic resonance angiography techniques to brain digital subtraction arteriography in the setting of mechanical thrombectomy: A non-inferiority study.

Revue neurologique·2022
Same author

Challenges and strategies for the delivery of biologics to the cornea.

Journal of controlled release : official journal of the Controlled Release Society·2021

Related Experiment Video

Updated: May 4, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.1K

Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.

H Ragelle1, R Riva2, G Vandermeulen1

  • 1Université Catholique de Louvain, Pharmaceutics and Drug Delivery Group, Louvain Drug Research Institute, 1200 Brussels, Belgium.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|January 7, 2014
PubMed
Summary
This summary is machine-generated.

This study developed PEGylated chitosan nanoparticles for safe and effective intravenous delivery of small interfering RNA (siRNA). These nanoparticles show high gene silencing and stability in blood, promising for siRNA therapeutics.

Keywords:
ChitosanGene silencingNanoparticlesStability in plasmasiRNA delivery

More Related Videos

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
08:36

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Published on: March 25, 2015

13.6K
Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles
05:36

Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles

Published on: October 4, 2024

2.2K

Related Experiment Videos

Last Updated: May 4, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.1K
Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
08:36

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Published on: March 25, 2015

13.6K
Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles
05:36

Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles

Published on: October 4, 2024

2.2K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Molecular Biology

Background:

  • Small interfering RNA (siRNA) holds therapeutic potential but requires effective delivery systems.
  • Chitosan nanoparticles are explored for drug delivery, but stability and efficacy for intravenous siRNA delivery need improvement.

Purpose of the Study:

  • To develop chitosan-based nanoparticles for intravenous siRNA delivery.
  • To achieve high gene silencing with low cytotoxicity and enhanced stability in biological media.

Main Methods:

  • Formulation of chitosan nanoparticles with varying ratios, physicochemical properties, PEGylation, and additives (endosomal disruptors, charged polymers).
  • Evaluation of gene silencing and cytotoxicity in B16 melanoma cells.
  • Assessment of siRNA nanoparticle stability in human plasma using fluorescence fluctuation spectroscopy and single particle tracking.

Main Results:

  • PEGylated chitosan and poly(ethylene imine) were crucial for high in vitro gene silencing.
  • Chitosan nanoparticles showed rapid siRNA release in plasma; hyaluronic acid and high PEG content improved particle stability.
  • Developed PEGylated chitosan nanoparticles demonstrated high gene silencing, low cytotoxicity, and good plasma stability.

Conclusions:

  • PEGylated chitosan-based nanoparticles are promising for intravenous siRNA delivery.
  • Formulation optimization is key to balancing gene silencing, cytotoxicity, and stability.
  • These nanoparticles represent a viable strategy for advancing siRNA therapeutics.